Operations

GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results

November 15, 2017

MEMPHIS, Tenn.–(BUSINESS WIRE)–GTx, Inc. (Nasdaq:GTXI) today reported financial results for the third quarter of 2017 and highlighted recent accomplishments and upcoming milestones.   “Kegels in a Bottle: Preliminary Results of a Selective Androgen Receptor Modulator (GTx-024) for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women” Tweet this “During the quarter, we achieved a key […]

Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV) today announced third quarter 2017 net revenue of $2.2 million compared to $1.9 million in net revenue for the same period in 2016. Net revenue for the nine months ended September 30, 2017 was $6.4 million compared to $3.1 million for the same […]

Ligand Provides Highlights from Today’s Analyst Day Event

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, including its revenue growth opportunities, its portfolio of partnered assets and its OmniAb® and Captisol® technology platforms. Management also discussed its Glucagon Receptor Antagonist internal development program, provided 2017 financial […]

Sage Therapeutics Prices Public Offering of Common Stock

November 15, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,529,411 shares of its common stock at a public offering price of $85.00 per share. The gross proceeds to Sage Therapeutics from the offering, […]

Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

November 15, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, today announced it has raised a $49 million Series A financing. The financing was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and Sanofi Ventures.   “With […]

Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update

November 15, 2017

LEXINGTON, Mass.–(BUSINESS WIRE)–Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited financial results for the quarter ended September 30, 2017.   Xenetic also provided a corporate update and anticipated milestones for […]

Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease

November 15, 2017

SAN FRANCISCO & TEL AVIV, Israel–(BUSINESS WIRE)–Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for US Patent Application 15/143,694 covering the use of cannabidiol (“CBD”) in the treatment of graft versus host […]

Turnstone Biologics Appoints Dr. Mike Burgess as President of Research and Development

November 15, 2017

OTTAWA, Ontario & NEW YORK–(BUSINESS WIRE)–Turnstone Biologics, a clinical-stage immuno-oncology company, today announced the appointment of Mike Burgess, MBChB, Ph.D., as president of research and development. Dr. Burgess joins from Bristol-Myers Squibb, where he was senior vice president of development across multiple therapeutic areas. At Turnstone Biologics, he will lead all functions in the R&D […]

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

November 15, 2017

ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update.   “We believe this financing will enable us to achieve several important milestones” Tweet this Third […]

PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry

November 15, 2017

BOSTON–(BUSINESS WIRE)–PAREXEL, a leading global biopharmaceutical services provider, today announced the appointment of three former senior regulatory consulting executives from the U.S. Food and Drug Administration (FDA) and Oncology industry positions. The new hires are part of PAREXEL’s Global Integrated Product Development and Compliance team and will be focused on helping PAREXEL clients deliver commercially […]

Motif Bio secures up to US$20 million debt financing

November 15, 2017

NEW YORK, Nov. 15, 2017 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has entered into an agreement for up to US$20 million in debt financing with Hercules Capital, Inc. (NYSE:HTGC), a leader in customised debt financing for companies in […]

WPI Biochemist Receives $1.7 Million NIH Award to Develop New Molecular Methods for Synthetizing Treatments for Drug-Resistant Cancers

November 15, 2017

Worcester, Mass. – Nov. 15, 2017 – Anita Mattson, associate professor of chemistry and biochemistry at Worcester Polytechnic Institute (WPI), has received a $1.7 million award from the National Institutes of Health (NIH) to develop a new class of catalysts that could make it possible to reliably synthesize organic compounds that hold the promise of […]

Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

November 15, 2017

Cambridge, Mass., November 15, 2017 – Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, today announced it has raised a $49 million Series A financing. The financing was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and […]

ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions

November 15, 2017

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ:ADMA) is a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and commercializes plasma-based biologics for the treatment of immune deficiencies and prevention of certain infectious diseases, announced today that the United States Patent and Trademark Office has […]

VBL Therapeutics Announces Third Quarter 2017 Financial Results

November 14, 2017

TEL AVIV, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced financial results for the three and nine months ended September 30, 2017 and provided a corporate update. “We were pleased to announce last week the […]

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

November 14, 2017

Geneva, Switzerland and Boston, MA – November 14, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today reported financial results for the third quarter ended September 30, 2017 and provided a business update […]

FDA Renews and Expands its Portfolio of Simcyp Simulator (PBPK) Licenses

November 14, 2017

Increased Use of Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulation (M&S) is a Priority in Both the Prescription Drug User Fee Act and Generic Drug User Fee Amendments Certara®, the global leader in model-informed drug development and regulatory science, today announced that the US Food and Drug Administration (FDA) has greatly expanded its use of Certara’s […]

FEEDBACK